← Leaderboards
Joshua James Meeks
Jesse Brown Va Medical Center
$1,485,005
Attributed
$2,970,010
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,970,010 · 1
VA$0 · 2
By mechanism
R01$2,970,010 · 1
I01$0 · 2
Top collaborators
- Ali Shilatifard1 shared
Others in their field
Other Emerging Leaders on “Carcinogens”
- Nikej Shah · Nirsum Laboratories, Inc.$12,506,430
- Florence Burleson · Brt-Burleson Research Technologies, Inc.$7,530,410
- Mary K. Schubauer-Berigan · International Agency For Res On Cancer$6,666,145
- Eunyoung Choi · Vanderbilt University Medical Center$5,366,751
- Silvia Balbo · Fred Hutchinson Cancer Research Center$4,458,163
- Cynthia A Moylan · Duke University$4,275,577
Research focus
CarcinogensRecurrenceEpigenetic ProcessMutationTumorMalignant Neoplasm Of Urinary BladderEnhancersCellsGenetic TranscriptionMolecularMalignant NeoplasmsFrequenciesSmokingTherapy ResistantPathway InteractionsBladderExposure ToLinkCause Of DeathNovel TherapeuticsVeteransResponseSomatic MutationBase
Grant awards (13)
Somatic Truncation Mutations of the Histone Methyltransferase MLL4 Alter Its Subcellular Localization in Bladder Cancer: Mechanistic Insight and Targeted Therapeutic Approach$2,970,010
R01 · FY2025 · CA
BCCMA: Basic and Translational Mechanisms of Cancer Initiation of the Urothelium in Veterans Exposed to Carcinogens: Defining the Molecular and Spatial Features of Carcinoma in situ of the Bladder$0
I01 · FY2025 · VA · contact PI
Epigenetic Regulation of Immune Evasion in Bladder Cancer$0
I01 · FY2024 · VA · contact PI
BCCMA: Basic and Translational Mechanisms of Cancer Initiation of the Urothelium in Veterans Exposed to Carcinogens: Defining the Molecular and Spatial Features of Carcinoma in situ of the Bladder$0
I01 · FY2024 · VA · contact PI
Epigenetic Regulation of Immune Evasion in Bladder Cancer$0
I01 · FY2023 · VA · contact PI
BCCMA: Basic and Translational Mechanisms of Cancer Initiation of the Urothelium in Veterans Exposed to Carcinogens: Defining the Molecular and Spatial Features of Carcinoma in situ of the Bladder$0
I01 · FY2023 · VA · contact PI
Epigenetic Regulation of Immune Evasion in Bladder Cancer$0
I01 · FY2022 · VA · contact PI
BCCMA: Basic and Translational Mechanisms of Cancer Initiation of the Urothelium in Veterans Exposed to Carcinogens: Defining the Molecular and Spatial Features of Carcinoma in situ of the Bladder$0
I01 · FY2022 · VA · contact PI
Epigenetic Regulation of Immune Evasion in Bladder Cancer$0
I01 · FY2021 · VA · contact PI
The Role of EZH2 in Non-Muscle Invasive Bladder Cancer$0
I01 · FY2020 · VA · contact PI
The Role of EZH2 in Non-Muscle Invasive Bladder Cancer$0
I01 · FY2019 · VA · contact PI
The Role of EZH2 in Non-Muscle Invasive Bladder Cancer$0
I01 · FY2018 · VA · contact PI
The Role of EZH2 in Non-Muscle Invasive Bladder Cancer$0
I01 · FY2017 · VA · contact PI